《大行報告》大和上調創科(00669.HK)目標價至200元 評級「買入」
大和發表報告,將創科實業(00669.HK)2021年至2023年的每股盈利預測提高11%至24%,以反映全球強勁的基礎設施建設和公司在無線產品方面的市場份額加速增長。
該行決定調高對創科目標價,由150元上調至200元,此相當預測市盈率30倍,維持「買入」評級,仍是該行的行業首選。
大和指,昨日在分析員會議中,創科管理層預計今年下半年將繼續保持遠高於行業的增長速度,並重申其超額業績並不是一次性。公司認為向無線產品的過渡仍處於早期階段,亦是其最大的收入優勢,而歐洲市場將帶來短期最大增長機會。創科管理層亦預計,公司在2024年前毛利率將繼續每年提高約50個基點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.